Carlsmed, Inc. Common Stock (CARL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carlsmed, Inc. Common Stock (CARL) has a cash flow conversion efficiency ratio of -0.141x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.01 Million) by net assets ($92.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Carlsmed, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Carlsmed, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Carlsmed, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CARL debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Carlsmed, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carlsmed, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INPAQ Technology Co Ltd
TWO:6284
|
0.036x |
|
Chemplast Sanmar Limited
NSE:CHEMPLASTS
|
0.039x |
|
Founders Metals Inc.
V:FDR
|
-0.013x |
|
Taiwan Fire & Marine Insurance Co Ltd
TW:2832
|
0.085x |
|
Baader Bank Aktiengesellschaft
F:BWB
|
N/A |
|
Jiangmen Kanhoo Industry Co Ltd
SHE:300340
|
-1.328x |
|
StealthGas Inc
NASDAQ:GASS
|
0.023x |
|
Shih Her Technologies
TWO:3551
|
-0.157x |
Annual Cash Flow Conversion Efficiency for Carlsmed, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Carlsmed, Inc. Common Stock from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see Carlsmed, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $98.87 Million | $-28.98 Million | -0.293x | -181.29% |
| 2024-12-31 | $-70.63 Million | $-25.47 Million | 0.361x | -4.85% |
| 2023-12-31 | $-46.13 Million | $-17.48 Million | 0.379x | -- |
About Carlsmed, Inc. Common Stock
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and … Read more